| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2022-01-04 |
| タイトル |
|
|
タイトル |
Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
cetuximab |
| キーワード |
|
|
主題 |
pharmacokinetics |
| キーワード |
|
|
主題 |
epidermal growth factor receptor |
| キーワード |
|
|
主題 |
interleukin-6 |
| キーワード |
|
|
主題 |
skin disorder |
| キーワード |
|
|
主題 |
head and neck cancer |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Shibata, Kaito
Naito, Takafumi
Hirakawa, Satoshi
Suzuki, Koji
Hosokawa, Seiji
Mineta, Hiroyuki
Kawakami, Junichi
|
| 書誌情報 |
Cancer Chemotherapy and Pharmacology
巻 87,
号 4,
p. 555-565,
発行日 2021-01-19
|
| 出版者 |
|
|
出版者 |
Springer Nature |
| 権利 |
|
|
権利情報 |
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s00280-020-04228-4 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Purpose: Cetuximab inhibits epidermal growth factor receptor (EGFR) signaling in cancer and skin cells, thereby inducing anti-cancer effects and skin disorders. The present study aimed to evaluate the relationships between serum cetuximab and EGFR-related markers, and adverse effects in head and neck cancer patients.
Methods: Thirty-four head and neck cancer patients receiving weekly intravenous cetuximab were enrolled. Serum cetuximab levels were determined just before dosing. Blood samples for determination of serum EGFR-related markers including soluble epidermal growth factor receptor (sEGFR) and interleukin-6 (IL-6) were obtained. The severities of skin disorders, their medications, and hypomagnesemia treatment were also assessed.
Results: Serum levels of cetuximab and sEGFR were negatively and positively correlated with that of IL-6, respectively. The serum cetuximab level was 2-fold higher in the patients with a grade 2–3 skin rash than with a grade 0–1 rash. The serum cetuximab cut-off value related to severe skin rash was 71 μg/mL (sensitivity, 59%; and specificity, 94%). The use of a strong topical corticosteroid for skin rash was also associated with a higher serum cetuximab level. Serum levels of sEGFR and IL-6 had no correlations with the skin disorder severities or their medications. Hypomagnesemia treatment using intravenous magnesium sulfate was not related to serum cetuximab and EGFR-related markers.
Conclusions: Head and neck cancer patients with a higher serum IL-6 level tended to have a lower serum cetuximab level. Serum cetuximab had positive correlations to skin rash severity and its medication in the study population. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0344-5704 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1432-0843 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
33462734 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s00280-020-04228-4 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
CCP-87-555.pdf (1.9 MB)
